Table 1 |
|||||||||
|
Clinicopathological features of patients with AITL-developed secondary EBV-associated B cell lymphoma described in present and previous reports |
|||||||||
|
caseNo. |
Authors (yr.) |
Age/sex |
Tumor site |
Interval (mo) |
Histotype of BCL* |
Treatment |
Clinical Outcome |
||
|
|
|
||||||||
|
AITL |
BCL |
AITL |
BCL |
||||||
|
|
|||||||||
|
1 |
Abruzzo LV (1993) [4] |
46/M |
LN |
SK |
26 |
Large-cell immunoblastic type |
Cyclophosphamide |
N/D |
Died of multiorgan failure |
|
2 |
Park S (2002) [5] |
55/F |
LN |
LN |
48 |
BCL |
CHOP |
CHOP-R |
CR and alive 12 mo later |
|
3 |
Xu Y (2002) [6] |
48/F |
LN |
LN |
0 |
DLBCL |
CHOP and ESHAP |
CR and relapsed a few months later |
|
|
4 |
Zettl A (2002) [7] |
68/M |
LN |
ST |
34 |
DLBCL |
Observation |
Glucocorticoids |
Died 4 mo later of tuberculosis |
|
5 |
47/M |
LN |
LN |
29 |
DLBCL |
CC; BMT |
CC; involved field radiation |
Died 3 mo later of Aspergillus pneumonia |
|
|
6 |
61/M |
LN |
LN |
96 |
Plasmacytoma |
N/Av |
N/Av |
Alive with disease 24 mo later |
|
|
7 |
Hawley RC (2006) [8] |
69/F |
LN |
SK |
56 |
DLBCL |
CHOP |
R-hyperCVAD |
Died 54 mo later |
|
8 |
Attygalle AD (2007) [9] |
28/M |
LN |
BM |
24 |
DLBCL |
CHOP |
Gemcitabine |
No response and died 3 mo later |
|
9 |
60/F |
LN |
LN |
8 |
DLBCL |
CHOP |
CHOP-Et |
No response and died 3 mo later |
|
|
10 |
59/M |
LN |
LN |
8 |
DLBCL |
N/Av |
CC |
PR and alive with disease 68 mo later |
|
|
11 |
72/M |
LN |
LN |
84 |
DLBCL |
N/Av |
N/Av |
N/A |
|
|
12 |
78/F |
LN |
LN |
0 |
DLBCL |
Thalidomide |
PR |
||
|
13 |
Willenbrock K (2007) [10] |
76/F |
LN |
LN |
8 |
DLBCL |
N/Av |
N/Av |
N/Av |
|
14 |
46/F |
LN |
BM |
5 |
DLBCL |
N/Av |
N/Av |
N/Av |
|
|
15 |
84/M |
LN |
LN |
0 |
DLBCL |
N/Av |
N/Av |
N/Av |
|
|
16 |
72/M |
LN |
LN |
0 |
DLBCL |
N/Av |
N/Av |
N/Av |
|
|
17 |
65/M |
LN |
LN |
0 |
CD30-positive BCL |
N/Av |
N/Av |
N/Av |
|
|
18 |
60/F |
LN |
LN |
0 |
DLBCL |
N/Av |
N/Av |
N/Av |
|
|
19 |
Weisel KC (2008) [11] |
59/M |
LN |
DB and lung |
11 |
DLBCL |
Fudarabine+ CHOP |
N/D |
Died 2 weeks later |
|
20 |
Takahashi T (2010) [12] |
66/F |
LN |
Ileum |
24 |
DLBCL |
THPCOP CHASE |
N/D |
Died 1 mo later of respiratory failure |
|
21 |
Skugor ND (2010) [13] |
36/F |
LN |
LN |
11 |
DLBCL |
FED |
CHOP-R and stem cell transplantation |
CR |
|
22 |
Huang J (2011) [14] |
64/M |
LN |
LN |
47 |
DLBCL |
IHOP |
CHOP-R |
Alive with disease 13 mo later |
|
23 |
Present case |
65/M |
LN |
SK |
19 |
DLBCL |
CHOP |
CHOP-R |
PR |
|
|
|||||||||
|
*, all B-cell lymphoma with EBV positive; AITL, angioimmunoblastic T-cell lymphoma; BCL, B-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; LN, lymph node; SK, skin; ST, soft tissue; BM, bone marrow; DB, Duodenal bulbus; Interval 0, AITL with simultaneous B-cell lymphoma or primary B-cell lymphoma in the background of AITL; BMT, bone marrow transplantation; N/Av, not available; N/D, not done; PR, partial response; CR, complete remission; CHOP, cyclophosphamide, vincristine, adriamycin, and prednisone; ESHAP, etoposide, methyl prednisolone, cytarabine (ara-C) and cisplatin; hyperCVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; IHOP, ifosfamide, doxorubicin, vincristine, and prednisone; THPCOP, cyclophosphamide, pirarubicin, vincristine, prednisolone; CHASE, cyclophosphamide, cytarabine, etoposide, dexamethasone; FED, fludarabine, cyclophosphamide, dexamethasone; Et, etoposide; R, rituximab; CC, combination chemotherapy, details not available; |
|||||||||
|
Yang et al. Diagnostic Pathology 2012 7:7 doi:10.1186/1746-1596-7-7 |
|||||||||
